Olga Golubnitschaja1,2,3, Jiri Polivka4,5,6, Kristina Yeghiazaryan1,2,3, Leonard Berliner7. 1. 1Department of Radiology, Rheinische Friedrich-Wilhelms-Universität Bonn, Sigmund-Freud-Str 25, 53105 Bonn, Germany. 2. 2Breast Cancer Research Centre, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 3. 3Centre for Integrated Oncology, Cologne-Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany. 4. 4Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic. 5. 5Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic. 6. 6Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic. 7. 7Interventional Radiology, Department of Radiology, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY USA.
Abstract
BACKGROUND: The annually recorded incidence of primary hepatic carcinomas has significantly increased over the past two decades accounting for over 800 thousand of annual deaths caused by hepatocellular carcinoma (HCC) alone globally. Further, secondary liver malignancies are much more widespread compared to primary hepatic carcinomas: almost all solid malignancies are able to metastasise into the liver. The primary tumours most frequently metastasising to the liver are breast followed by colorectal carcinomas. Given the increased incidence of both primary and metastatic liver cancers, a new, revised approach is needed to advance medical care based on predictive diagnostics, innovative screening programmes, targeted preventive measures, and patient stratification for treatment algorithms tailored to individualised patient profile. ADVANTAGES OF THE APPROACH TAKEN: The current pilot study took advantage of systemic alterations characteristic for liver malignancies, utilising liquid biopsy (blood samples) and specific biomarker patterns detected. Key molecular pathways relevant for pathomechanisms of liver cancers have been considered opening a perspective for both-individualised diagnostics and targeted treatment. Systemic alterations have been analysed prior to the therapy application avoiding molecular biological effects potentially diminishing predictive power of the biomarker-panel proposed. Multi-omics at DNA and protein (both expression and activity) levels has been applied. An established biomarker panel is considered as a powerful tool for individualised patient profiling and improved multi-level diagnostics-both predictive and prognostic ones. RESULTS AND CONCLUSIONS: Biomarker panels have been created for the patient stratification, prediction of a more optimal therapy and prognosis of survival based on the individualised patient profiling. Although there are some limitations of the pilot study performed, the results are encouraging, as it may be possible, through further research along these lines, to find a clinically and cost-effective means of stratifying liver cancer patients for personalised care and therapy. The benefits to the patient and society of accurate treatment stratification cannot be overemphasised.
BACKGROUND: The annually recorded incidence of primary hepatic carcinomas has significantly increased over the past two decades accounting for over 800 thousand of annual deaths caused by hepatocellular carcinoma (HCC) alone globally. Further, secondary liver malignancies are much more widespread compared to primary hepatic carcinomas: almost all solid malignancies are able to metastasise into the liver. The primary tumours most frequently metastasising to the liver are breast followed by colorectal carcinomas. Given the increased incidence of both primary and metastatic liver cancers, a new, revised approach is needed to advance medical care based on predictive diagnostics, innovative screening programmes, targeted preventive measures, and patient stratification for treatment algorithms tailored to individualised patient profile. ADVANTAGES OF THE APPROACH TAKEN: The current pilot study took advantage of systemic alterations characteristic for liver malignancies, utilising liquid biopsy (blood samples) and specific biomarker patterns detected. Key molecular pathways relevant for pathomechanisms of liver cancers have been considered opening a perspective for both-individualised diagnostics and targeted treatment. Systemic alterations have been analysed prior to the therapy application avoiding molecular biological effects potentially diminishing predictive power of the biomarker-panel proposed. Multi-omics at DNA and protein (both expression and activity) levels has been applied. An established biomarker panel is considered as a powerful tool for individualised patient profiling and improved multi-level diagnostics-both predictive and prognostic ones. RESULTS AND CONCLUSIONS: Biomarker panels have been created for the patient stratification, prediction of a more optimal therapy and prognosis of survival based on the individualised patient profiling. Although there are some limitations of the pilot study performed, the results are encouraging, as it may be possible, through further research along these lines, to find a clinically and cost-effective means of stratifying liver cancer patients for personalised care and therapy. The benefits to the patient and society of accurate treatment stratification cannot be overemphasised.
Authors: Aurora De Ponti; Lars Wiechert; Doris Schneller; Tobias Pusterla; Thomas Longerich; Nancy Hogg; Arndt Vogel; Peter Schirmacher; Jochen Hess; Peter Angel Journal: Cancer Lett Date: 2015-09-21 Impact factor: 8.679
Authors: P Miller; K M Kidwell; D Thomas; M Sabel; J M Rae; D F Hayes; B I Hudson; D El-Ashry; M E Lippman Journal: Breast Cancer Res Treat Date: 2017-07-17 Impact factor: 4.872
Authors: Jiri Molacek; Vladislav Treska; Jan Zeithaml; Ivana Hollan; Ondrej Topolcan; Ladislav Pecen; David Slouka; Marie Karlikova; Radek Kucera Journal: EPMA J Date: 2019-06-03 Impact factor: 6.543
Authors: Pavol Zubor; Peter Kubatka; Karol Kajo; Zuzana Dankova; Hubert Polacek; Tibor Bielik; Erik Kudela; Marek Samec; Alena Liskova; Dominika Vlcakova; Tatiana Kulkovska; Igor Stastny; Veronika Holubekova; Jan Bujnak; Zuzana Laucekova; Dietrich Büsselberg; Mariusz Adamek; Walther Kuhn; Jan Danko; Olga Golubnitschaja Journal: Int J Mol Sci Date: 2019-06-13 Impact factor: 5.923
Authors: Elvin T Ng; Russell Z Ang; Bach X Tran; Cyrus S Ho; Zhisong Zhang; Wanqiu Tan; Yu Bai; Min Zhang; Wilson W Tam; Roger C Ho Journal: Int J Environ Res Public Health Date: 2019-12-06 Impact factor: 3.390